Listen to the audio version of this article (generated by AI).
When executives buy shares of their own companies, I pay attention. They know their businesses better than most outside investors. But insider buying is a starting point for research, not a reason to rush into a trade.
Three healthcare stocks have made my watchlist: Prothena Corporation (PRTA), Rapport Therapeutics, Inc. (RAPP) and Azenta, Inc. (AZTA). Prothena and Rapport have reported insider purchases. Azenta is a different story: the company has been buying back its own stock. I want to know who is buying, whether the business has the financial strength to weather setbacks, and what could move the stock next. None of these three is an immediate trade recommendation.
Why Insider Buying Alone Is Not Enough
Boston Scientific Corporation (BSX) is a useful caution from my November 10 discussion. Its CEO put about $9 million of his own money into the stock through 10 open-market purchases. Then on October 28, the company cut its full-year sales growth outlook to about 4.25% from 5.5% and said fourth-quarter sales would fall. The stock dropped as much as 12%. Even a substantial executive purchase can’t protect shareholders from a guidance cut. So I treat insider buying as a reason to investigate. It doesn’t tell me a stock will rise. Before I consider a setup, I want a meaningful buyer, enough cash to survive and a catalyst with a timetable. I also want to know what would change my mind.
Prothena Stock (PRTA): Insider Interest and Alzheimer’s Trial Data
Prothena is a biotechnology company developing treatments for neurological diseases. An SEC Form 4 confirms that William P. Scully, identified as a 10% owner, purchased 27,000 shares on September 2, 2026, at a weighted-average price of $9.4718 per share. That is a documented shareholder purchase, distinct from Prothena’s corporate repurchase program.
The balance sheet is part of the appeal. Prothena reported $272.2 million in cash, cash equivalents and restricted cash and no debt as of September 30, 2026. It also reported buying back $26.6 million of shares during the first nine months of the year under a program of up to $100 million scheduled to expire December 31, 2026. Those figures come from its November 5 earnings release.
The catalyst: Bristol Myers Squibb’s Phase 2 study in early Alzheimer’s disease, with data expected in the first half of 2027, according to Prothena’s November 5 release.
My take: Prothena is on my watchlist because of a potentially significant clinical event. The science could disappoint, and cash on the balance sheet is no guarantee of a floor under the share price. I also want to see whether buying support continues and what happens when the current repurchase authorization expires.
Rapport Therapeutics Stock (RAPP): Director Buying and Epilepsy Data
Rapport Therapeutics develops treatments for neurological and psychiatric conditions. SEC Form 4 filings show that five directors and the chief financial officer bought roughly $1.66 million of shares in October 2026, at prices around $26.10 to $27.35. That figure does not include a separate large director purchase tied to an October financing.
Rapport reported $395.0 million in cash, cash equivalents and short-term investments as of September 30, 2026. Following October securities offerings and a November at-the-market sale, it estimated $815.4 million on November 3, including the proceeds of those transactions. The company said the financing should extend its operating runway through the end of 2029.
The catalyst: Rapport expects data from its open-label long-term safety study in focal-onset seizures in the fourth quarter of 2026. The company also has a planned FDA interaction concerning its bipolar mania program in the first quarter of 2027, according to its November update.
My take: I like seeing insiders commit their own money, particularly when there’s enough capital to fund development. Rapport’s October offering was priced at $21 a share, and insiders were still buying around $26. But clinical-stage biotechnology carries real trial and dilution risk. I’m watching the data and any change in insider behavior. I am not recommending an options trade here.
Want to see how I evaluate a setup before trading it?
Join my free Masters in Trading updates for market analysis, trading education and the risk factors I’m watching.
Azenta Stock (AZTA): Share Buybacks and a Potential Growth Turnaround
Azenta supplies sample-storage and genomics services to the life-sciences industry. It is my favorite of the three.
In its August 4 fiscal third-quarter report, Azenta disclosed repurchasing 2.3 million shares for $50.0 million under its 2025 repurchase program. It also reported $529 million in cash and marketable securities and no debt on its June 30 balance sheet.
The catalyst: Azenta’s fiscal 2027 outlook. I want to see whether organic revenue growth can improve from the flat-to-1% range discussed in its fiscal 2026 guidance. A buyback is more interesting to me if the underlying business also starts to improve.
My take: This is a potential self-help story. Cash and repurchases caught my attention. But I still want evidence of a business improvement before putting on a trade. When I discussed Azenta in my November 10 session, its fiscal fourth-quarter report was still hours away, and the fiscal 2027 outlook in that report was my test of whether the turnaround is real.
Editor’s note: After the market closed on November 10, Azenta guided fiscal 2027 organic revenue growth of 3% to 5%, compared with 2% organic growth in fiscal 2026, on revenue of about $648 million to $660 million. The company said it repurchased 4.4 million shares for $118.2 million in fiscal 2026 and ended September with $506 million in cash, cash equivalents, restricted cash and marketable securities. Jonathan’s comments above were made before the report.
Watch My Full Healthcare Stock Analysis
Want to hear me walk through these names in real time? Here’s my November 10 Masters in Trading: Live session, recorded before Azenta’s fiscal fourth-quarter report, where I explain why Azenta is my favorite of the three.
What Would Make These Healthcare Stocks Worth Trading?
I’m not treating any of these names as a buy just because insiders or the companies themselves bought shares. My decision would depend on whether the catalyst develops as expected, whether the company has enough cash to absorb setbacks and whether the stock offers a trade with manageable downside.
| Stock | Buying signal | What I’m watching |
|---|---|---|
| Prothena (PRTA) | Reported major-holder purchase; company buyback | Alzheimer’s trial data expected in first half of 2027 |
| Rapport (RAPP) | Reported purchases by directors and CFO | Seizure-study data and regulatory milestones |
| Azenta (AZTA) | Corporate share repurchases | Fiscal 2027 organic-growth outlook (released Nov. 10) |
With Prothena and Rapport, disappointing clinical data or a reversal in buying behavior would change the picture. With Azenta, a weak growth outlook could outweigh the appeal of repurchases. The biggest risk I see is rates. The S&P 500 had its worst week since April 2025 in the five trading days ending November 6. Healthcare stocks aren’t immune to higher rates, and if rate pressure continues into 2027, riskier names like these get harder to own.
My bottom line: buying activity tells me where to look, and a dated catalyst gives me something concrete to evaluate. None of that replaces an exit plan.
Follow the Setups I Am Watching
I’ve spent decades trading and studying how markets react to catalysts, earnings and changing expectations. In my free Masters in Trading coverage, I explain the setups I’m watching and the risks that could make me change my mind. If you want to learn how I approach a trade before putting money at risk, join me.
Insider Buying: Frequently Asked Questions
Does insider buying mean a stock will rise?
No. Insider purchases may indicate confidence, but executives can be early or wrong. Boston Scientific is a reminder to evaluate earnings, guidance and downside risk alongside insider transactions.
Are stock buybacks the same as insider buying?
No. Insider buying typically refers to purchases by company insiders using their own funds. A buyback uses corporate funds to repurchase shares. Azenta belongs in the second category based on the evidence discussed here.
Which three healthcare stocks is Jonathan Rose watching?
Prothena (PRTA), Rapport Therapeutics (RAPP) and Azenta (AZTA). In his November 10 session, Rose identified Azenta as his favorite of the three, but did not recommend an immediate trade in any of them.
Finding Healthcare Stocks Worth Watching Is Just the Beginning
Insider purchases, corporate buybacks and upcoming clinical trials can all point to potential opportunities. But as we’ve seen, none guarantees a winning trade.
That’s why I look beyond the headlines to evaluate the catalysts, risks and market conditions that could influence a stock’s next move.
In my free Masters in Trading: Live sessions, I break down opportunities like these, explain what I’m watching and share how I approach potential trades.
This article is for educational purposes only and is not investment advice.
